Thus, cholestasis or SIRT6 agonists, which likely interfere with the flow of bile acids into the small intestine, may reduce the population of bile acid-metabolizing bacteria but lead to an overgrowth of other harmful bacteria in the gut. The gene discussed is SIRT6; the disease is cholestasis.